The studies making these observations were focussed on the impact of PI3K inhibitors on the tumour vasculature in cancer, and suggest that the vascular effects of these drugs can be used to improve drug delivery to tumours while also facilitating immune cell recruitment [183–186]. The gene discussed is PIK3CG; the disease is neoplasm.